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hERG   Human ether-a-go-go protein; α-subunit of hERG protein complex 
KvLQT1  α-subunit of KvLQT1 protein complex  
hERG (KCNH2) Gene encoding α-subunit hERG  
KCNE1  Gene encoding α-subunit KvLQT1 
APD   Action potential duration 
MiRP1   MinK-related protein 1; β-subunit of hERG protein complex 
minK   β-subunit of KvLQT1 protein complex  
IKr   Rapid-delayed rectifying potassium current through hERG channel  
IKs   Slow-delayed rectifying potassium current through KvLQT1 channel 
LQTS   Long QT Syndrome 
CNBhD  Cyclic Nucleotide Binding homology Domain 
CHOs   Chinese Hamster Ovary Cells 
HEKs   Human Embryonic Kidney Cells 
wt   Wild-type 
pCPT-cAMP  8-(4-Chlorophenylthio)adenosine 3’,5’-cyclic monophosphate  
   sodium salt 
IBMX   3-Isobutyl-1-methlxanthine 
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apFRET  Acceptor photobleaching fluorescence resonance energy transfer 
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KvLQT1 and hERG are the voltage-gated K
+
 channel α-subunits of the cardiac 
repolarizing currents IKs and IKr, respectively. These currents function to maintain proper 
action potential durations in cardiomyocytes to ultimately promote a normal heartbeat. 
Mutations in KCNQ1 or hERG can lead to a loss of proper function in these currents, 
resulting in arrhythmias. Previous research in transgenic model organisms demonstrated 
that interactions between pore mutants of KvLQT1 and hERG exist, resulting in mutual 
downregulation of their respective currents. In addition, direct protein-protein 
interactions between wild-type hERG and KvLQT1, and more specifically between the 
COOH-termini of the two proteins, have been established. These interactions have been 
shown to result in downregulation of the repolarizing currents in heterologous cells. We 
hypothesize that hERG-KvLQT1 interactions are abrogated through direct binding of 
cAMP to the cyclic nucleotide binding homology domain (CNBhD) in the C-terminus of 
hERG, rather than by downstream, PKA-mediated effects. In order to delineate the 
molecular mechanism underlying these interactions, quantitative FRET analyses were 
performed on human embryonic kidney (HEK) cells co-expressing either wild-type 
hERG and KvLQT1, or the V822M hERG mutant and wild-type KvLQT1. Intracellular 
cAMP levels were elevated through membrane-permeable cAMP analogs and IBMX. 
Mean FRET efficiency of wild-type hERG and KvLQT1 was significantly reduced in the 
presence of elevated intracellular cAMP levels, while the mean FRET efficiency of 
mutant hERG and KvLQT1 was not significantly affected. The effect of elevated cAMP 
levels on the interactions between wild-type hERG and KvLQT1 compared to those 
between mutant hERG and KvLQT1 still remains inconclusive. In light of current 
progress in the field, however, the potential for cAMP-dependent PKA phosphorylation 
of hERG and/or KvLQT1 will also be explored. This work potentially furthers our 
understanding of the physiological regulation of hERG-KvLQT1 interactions and its 
implications on cardiac arrhythmias in both healthy and diseased states, as well as 





















 The heart acts as a mechanical pump responsible for delivering oxygenated blood 
to all of the cells of the body. The mechanical function of this organ is regulated by 
synchronous electrical activity of the muscle cells of the heart, referred to as 
cardiomyocytes. In humans, the cardiac action potential is dependent on the influx and 
efflux of various ions and can be divided into five distinct phases (Sanguinetti and 
Tristani-Firouzi, 2006). Depolarization occurs during phase 0 of the action potential and 
is a result of a rapid influx of sodium, referred to as the sodium current, or INa, while 
repolarization is mainly the result of the efflux of potassium ions (Grant, 2009). In the 
cardiomyocyte, repolarization is a much slower process (Figure 1), occurring over the 
course of phases 1, characterized by a rapid, short depolarization, 2, characterized by a 
plateau of repolarization, 3, characterized by a more prominent depolarization of the 
membrane potential, and 4, characterized by complete repolarization and representative 
of the resting membrane potential, which would continually persist without the triggered 
influx of sodium to effectively restart the cycle (Sanguinetti and Tristani-Firouzi, 2006). 
The collective activity of multiple cardiomyocytes results in activity at the organ level, 













There are multiple kinds of potassium currents responsible for repolarization, 
while only one kind of sodium current exists for depolarization (Grant, 2009). There are 
then different kinds of potassium channels responsible for the different potassium 
currents. Specifically, there are 7 different potassium currents that are regulated by 5 
different potassium channels (Grant, 2007).  
hERG and KvLQT1 are two voltage-gated potassium channel protein subunits 
located in the plasma membrane of cardiomyocytes. The currents they carry are 
responsible for repolarizing the cardiac action potential during phase 3 of the cardiac 
action potential, as well as during phase 2 to offset the Ca
2+
 current, resulting in the 
characteristic plateau (Vandenberg et al., 2012; Jespersen et al., 2005).  These 
repolarizing currents are essential to maintain proper action potential durations (APD) in 
cardiomyocytes to ultimately promote a normal heartbeat (Beeler and Reuter, 1977). Loss 
Figure 1. The top figure depicts a 
normal surface ECG recording, and the 
figure below represents the 
corresponding action potential for a 
normal cardiomyocyte. The P wave 
represents atrial depolarization, the 
QRS complex represents atrial 
repolarization and simultaneous 
ventricular depolarization, and the T 
wave represents ventricular 
repolarization. The action potential 
demonstrates the various phases that 















of proper function in these currents can result in arrhythmias and, if untreated, sudden 
cardiac arrest (Sanguinetti and Tristiani-Firouzi, 2006). There are multiple potassium 
channels involved in maintaining APD, believed to be involved in a compensatory 
mechanism, or “repolarization reserve”, in the event that one channel loses or alters its 
function (Roden, 2008). Previous studies on transgenic model organisms of long QT 
syndrome (LQTS) demonstrated that the presence of mutant KvLQT1 resulted in the 
expected loss of IKs, as well as an unexpected, functional downregulation of IKr, and vice 
versa (Brunner et al., 2008). This functional, mutual downregulation of hERG and 
KvLQT1 suggests that these proteins are somehow interacting, or “communicating”, with 
one another, which may have negative physiological consequences. 
 
hERG (KCNH2) 
 hERG (human ether-a-go-go related gene), or KCNH2, is located on chromosome 
7 and specifically encodes the pore-forming α-subunit protein of the hERG channel that 
is responsible for the IKr current (Vandenberg et al., 2012). hERG is 1159 amino acids 
long with a cyclic nucleotide binding homology domain (CNBhD) located in the COOH-
terminus (Warmke and Ganetzky, 1994; Vandenberg et al., 2012). The α-subunit of this 
channel possesses 6 transmembrane regions (Vandenberg et al., 2012). Four, identical α-
subunits come together to form the pore of the channel through which potassium ions 
flow (Vandenberg et al., 2012). As an ion channel complex, hERG also assembles with 
its β-subunit, MinK-related peptide 1 (MiRP1), which is encoded by the gene KCNE2, 
although it does not appear that the expression of MiRP1 is necessary for hERG function, 





1999; Weerapura et al., 2002). A visual representation of hERG and MiRP1 in the cell 
















KCNQ1 is located on chromosome 11 and encodes the α-subunit of the KvLQT1 
channel that assembles with the KCNE1 β-subunit (minK) and forms a channel complex 
constituting the delayed rectifier current IKs in cardiomyocytes (Barhanin et al., 1996; 
Sanguinetti et al., 1996; Jespersen et al., 2005). A single KvLQT1 subunit also possesses 
6 transmembrane regions (Jespersen et al., 2005). The α-subunit is 676 amino acids in 
length, four of which come together to form the homotetrameric KvLQT1 channel pore 
Figure 2. (A) represents the topology of 
the hERG α subunits that may assemble 
with MiRP1 (B) to form the IKr channel. 
The localization and function of MiRP1 
are still relatively unknown and under 
investigation. The black dots represent 
the location of various identified 
mutations of hERG and MiRP1 
associated with different forms of LQT 






(Jespersen et al., 2005). β-subunit assembly with the α-subunits in this case is critical for 
proper IKs production (Barhanin et al., 1996; Sanguinetti et al., 1996). A visual 





















Figure 3. (A) represents the 
topology of the KvLQT1 and 
minK subunits forming the IKs 
potassium channel. Note the 
location of the minK subunit in 
relation to KvLQT1, this allows 
minK to interact with the ion 
channel portion of KvLQT1 and 
delay inactivation of the channel. 
(B) represents a three dimensional 
depiction of the KvLQT1-minK 
channel complex in the plasma 







The redundancy in the function of the repolarizing currents and the presence of 
different kinds of potassium channels suggest a potential evolutionary purpose for 
multiple repolarizing potassium channels proteins. This concept of a “repolarization 
reserve” has been characterized as a failsafe type of mechanism for maintenance of 
normal APD in the event that one potassium channel is blocked or impaired under normal 
physiological conditions (Biliczki et al., 2002). However, in the case that the current 
density of one of the channels is decreased as a result of genetic inheritance, such as in 
certain forms of LQTS, a cardiac condition in which the QT phase observed on an ECG 
(Figure 1) is prolonged, the “repolarization reserve” is essentially depleted because one 
channel is mutated, placing these patients at an increased risk for arrhythmia (Biliczki et 
al., 2002).   
Brunner et al. (2008) reported two transgenic rabbit models of LQTS in which 
there was a dominant-negative overexpression of the pore mutants of KvLQT1, 
corresponding to LQT1, or pore mutants of hERG, corresponding to LQT2. Expression 
of these pore mutants resulted in the loss of IKs and IKr currents, respectively, as expected 
(Brunner et al., 2008). However, they also observed a significant downregulation of the 
complementary currents, IKr and IKs, respectively, without any evidence of decreased 
protein expression levels (Brunner et al., 2008). This physiological observation suggested 
the presence of dynamic hERG-KvLQT1 interactions (Brunner et al., 2008). 
The results from Brunner et al. (2008) demonstrating the mutual, functional 
downregulation of IKs and IKr in the transgenic rabbit models of LQT syndrome prompted 





Ren et al. (2010), due to the difficulty of culturing primary cardiomyocytes as well as the 
complexity in analyzing single currents in an excitable cell system. They found that 
transiently expressing pore mutant or wild-type (wt) KvLQT1 in Chinese Hamster Ovary 
cells (CHOs) stably expressing wt hERG both resulted in significant downregulation of 
IKr (Ren et al., 2010). They observed a similar downregulation of IKs when pore mutant or 
wt hERG was transiently expressed in CHOs stably expressing wt KvLQT1 (Ren et al., 
2010). Furthermore, they found that (1) the deletion of the NH2-terminus of KvLQT1 did 
not eliminate interactions, suggesting that the N-terminus of KvLQT1 is not necessary for 
these interactions, (2) co-immunoprecipitations demonstrated specific interactions 
between hERG and KvLQT1; and (3) surface plasmon resonance experiments 
demonstrated that the C-termimus of KvLQT1 interacts directly with C-terminus of 
hERG (Ren et al., 2010). 
Additional studies have also demonstrated that hERG and KvLQT1 interact 
directly and specifically. Ehrlich et al. (2004) determined that hERG and KvLQT1 
interact based on biophysical and biochemical evidence. They found that hERG current 
density doubled when hERG was co-expressed with KvLQT1, while membrane 
localization of hERG also increased when KvLQT1 was co-expressed (Ehrlich et al., 
2004). Biliczki et al. (2009) demonstrated that expressing a trafficking-deficient KvLQT1 
mutant failed to enhance membrane localization of hERG and reduced the IKr current that 
is normally observed in the presence of wt KvLQT1. These results suggest the potential 
role of such interactions and/or the disturbances in these interactions in attributing to the 





Organ-Darling et al. (2013) went on to assess the nuances of the hERG-KvLQT1 
interactions in human embryonic kidney (HEK) cells, another heterologous cell line 
useful as an in vitro model system, and in primary neonatal rabbit cardiomyocytes using 
acceptor photobleach fluorescence resonance energy transfer (apFRET) experiments, a 
quantitative method for measuring protein interactions in intact cells. Organ-Darling et al. 
(2013) were able to measure FRET efficiencies to demonstrate direct hERG-KvLQT1 
interactions between the C-termini of the two proteins. Moreover, they demonstrated that 
increasing intracellular cAMP levels via acute treatment of hERG- and KvLQT1-
expressing cells with two chemicals, IBMX, a phosphodiesterase inhibitor, and pCPT-
cAMP, a permeable analogue of cAMP, together reduced these interactions. These 
results, in addition to the presence of a CNBhD in the portion of hERG that interacts with 
KvLQT1, suggested a direct role of the CNBhD in mediating these interactions (Warmke 
and Ganetzky, 1994; Organ-Darling et al., 2013). Therefore, this study provides the 
motivation for the focus of my thesis specifically addressing the role of the CNBhD and 
cAMP in mediating hERG-KvLQT1 interactions at the molecular level. 
Cyclic adenosine 3’,5’-monophosphate (cAMP) is a ubiquitous secondary 
messenger found in a wide range of cell types responsible for a diverse range of cellular 
signaling pathways and functions (Fimia and Sassone-Carsi, 2001). One of its functions 
is to activate the enzyme protein kinase A (PKA), which phosphorylates many kinds of 
proteins that are involved in a variety of pathways within the cell (Fimia and Sassone-
Carsi, 2001). More specifically in cardiac physiology, cAMP levels increase as a result of 
epinephrine binding to its G-protein coupled receptor, the β-adrenergic receptor, resulting 





The secondary messenger then goes onto activate PKA, which goes onto phosphorylate a 
host of other protein targets, one of which includes KvLQT1 (Benovic et al., 1986). The 
KvLQT1 phosphorylation pathway has been generally well-characterized. The IKs current 
increases in response to inputs from the sympathetic nervous system in order to increase 
heart rate and contractility, and to shorten the APD (Cheng et al., 2004). Marx et al. 
(2002) reported that cAMP-dependent PKA activity is responsible for phosphorylating 
KvLQT1 and its β-subunit minK (Marx et al., 2002). They also reported that elevating 
cAMP levels resulted in an increase in IKs, while the S27A substitution at a KCNQ1 
phosphorylation site eliminated cAMP-dependent enhancement of the KCNQ1-KCNE1 
current (Marx et al., 2002). The same pathway involving cAMP-dependent KvLQT1 
phosphorylation at the N-terminus by PKA was elucidated by and expanded upon by 
other groups (Kurokawa et al., 2003; Nicholas et al., 2008) 
Because cAMP is involved in many cellular processes, it would be a reasonable to 
speculate that downstream, PKA-mediated effects are responsible for modulating the 
direct interactions between hERG and KvLQT1 through hERG phosphorylation, and that 
the role of cAMP in this pathway is its general function of activating PKA (Cui et al., 
2001). Indeed it appears that PKA does phosphorylate hERG downstream of adenylyl 
cyclase activity, thereby altering hERG channel electrophysiology (Cui et al., 2000; 
Kiehn, 2000). However, the presence of a CNBhD on the C-terminus of hERG suggests 
that cAMP plays a more direct role in the modulation of hERG-KvLQT1 interactions 
(Warmke and Ganetzsky, 1994; Cui et al. 2000). 
A CNBD homology domain is present in various families of ion channels, 





hyperpolarization-activated cyclic-nucleotide-modulated family, and the cyclic-
nucleotide-gated family (Akhavan et al., 2005; Brelidze et al., 2009). Typically, its 
presence on channels suggests that these proteins are directly modulated by a cyclic 
nucleotide such as cAMP or cGMP (Akhavan et al., 2005). Previous studies have 
demonstrated that mutations or defects in the CNBhD of eag and KCNH channels have 
resulted in abnormal protein trafficking (Cui et al., 2001; Akhavan et al., 2005). Akhavan 
et al. demonstrated that the removal of the entire CNBhD on hERG prevented normal 
trafficking and surface expression, and thus function, of the hERG complex (Akhavan et 
al., 2005). Satler et al. (1996) identified a specific missense mutation in the CNBhD of 
hERG, in which the highly conserved valine at position 822 is replaced with a 
methionine, which appears to cause LQT2 by disrupting the function of the domain and 
thus causing an abnormal repolarizing current. The V822M mutation in hERG associated 
with LQT syndrome, along with the similarities between the CNBhD of hERG and other 
cyclic nucleotide gated channels, suggests that cAMP is involved in modulating hERG 
function and excitability (Bruggemann et al., 1993; Satler et al. 1996).  
However, it should be noted that we refer to the CNBD on hERG as a “homology 
domain” due to contending views about the true ability of this domain to bind cAMP.  
Cui et al. (2000) suggest that cAMP mediates hERG function via two parallel pathways 
involving PKA downstream of cAMP and the direct binding of cAMP at the CNBhD. In 
order to test the role of PKA-mediated phosphorylation of hERG on hERG function, the 
group utilized the specific peptide inhibitor PKI (Cui et al., 2000). They also identified 
and mutagenized PKA phosphorylation sites on hERG to prevent phosphorylation from 





hERG did not occur under these conditions (Cui et al., 2000). In order to test the direct 
role of the CNBhD in regulating hERG currents, binding assays of labeled cAMP to 
hERG were performed in vitro (Cui et al., 2000). Electrophysiology experiments were 
also performed to assess these effects on hERG function (Cui et al., 2000). Ultimately, 
the combinatory effects of cAMP-dependent PKA phosphorylation of hERG and direct 
binding of cAMP to hERG resulted in a decreased hERG current (Cui et al., 2000). 
Interestingly, however, Cui et al. (2000) also observed that in the presence of β-subunit 
proteins MiRP1 or minK, the stimulatory effects of direct cAMP binding on IKr was 
accentuated. 
While groups, such as Thomas McDonald’s group at Albert Einstein College of 
Medicine, which includes members from Cui et al. (2000), have claimed that cAMP 
directly binds to the CNBD on hERG, others have contended this view. Brelidze et al. 
(2009) reported that cAMP binds with very low affinity to the CNBhD of isolated hERG1 
proteins, and that this binding does not affect hERG current, even at high concentrations 
of cAMP. Li et al. (2014) utilized NMR to demonstrate that cAMP does not directly bind 
to the CNBD on hERG. Others have determined the crystal structures of isolated 
CNBhDs of various KCNH channels, such as EAG and EAG-like channels (Brelidze et 
al., 2012; Marques-Carvalho et al., 2012). They have shown that these CNBhDs do not 
bind cyclic nucleotides and are instead occupied by short β-strands or COOH-terminus 
residues (Brelidze et al., 2012; Marques-Carvalho et al., 2012). Brelidze et al. (2012) 
have also shown that mutating these β-strands, preventing them from binding to the 





“self-liganded”. These studies shed light onto the possibility that the CNBhD may not 
actually play a direct role in hERG-KvLQT1 interactions. 
The Darling lab is actively seeking to illuminate the cellular and molecular 
mechanisms of the direct interactions between hERG and KvLQT1 and to determine the 
functional consequences of such interactions. Initially, we hypothesized that the direct 
hERG-KvLQT1 interactions are modulated by direct binding of the ubiquitous 
intracellular signaling molecule cAMP at the CNBhD located in the COOH-terminus of 
hERG. The following experiments were performed in order to address this particular role 
of the CNBhD of hERG in mediating these interactions. However, do note that due to the 
current perspective of the field as described above, we understand that the PKA-mediated 
pathway is of biological significance to study in the future. Elucidating the underlying 
mechanisms regulating hERG-KvLQT1 interactions may help to understand the 
molecular origins of many types of arrhythmias and LQTS, as well as to aid in the 




The first aim of my thesis was to assess the role of intracellular cAMP levels in 
modulating hERG-KvLQT1 interactions at the molecular level. Again, the presence of 
direct interactions between hERG and KvLQT1 has been identified based on results from 
previous studies demonstrating the ability of KvLQT1 to rescue hERG protein trafficking 
to the cell membrane (Ehrlich et al., 2004), as well as other studies utilizing FRET and 
co-IP methodologies to show that hERG and KvLQT1 interact when co-expressed in in 





In order to address this question, acceptor photobleach FRET, or apFRET, 
experiments were performed in HEK cells expressing wt hERG and KvLQT1 tagged with 
fluorophores mCFP and mYFP, respectively. FRET, or Forster (fluorescence) resonance 
energy transfer, is a physical phenomenon that occurs between two light-sensitive 
molecules, which involves the radiation-less transfer of energy from a “donor” molecule 
to an “acceptor” molecule (Sun et al., 2013). Figure 4 provides a representation of the 
FRET phenomenon and how it is utilized in apFRET experiments. While the role of 
cAMP has been introduced previously by Organ-Darling et al. (2013), it was still of 
significant importance to validate the reproducibility of these results as a part of my 
project because ongoing apFRET experiments are performed on instrumentation and 
software different from those utilized in the Organ-Darling et al. study (2013). 
 
 
Figure 4. The diagram on the left demonstrates FRET, which is the radiation-less transfer of 
energy from a donor to an acceptor molecule, using fluorescence pairs. The laser excites electrons 
in the molecule to a higher energy level and transfers that energy to the neighboring molecule. 
These electrons then fall back to their original energy level, emitting light. The diagram on the 
right relates this principle to the use of fluorophores attached to proteins. When the two proteins 
are within 10nm of each other, a laser can excite one fluorophore and the energy will be 
transferred and emitted form the second fluorophore. The color change of the emission signals the 
energy transfer. The efficiency of this transfer can be quantified. Figures created and adapted 






Prior to performing apFRET experiments, it was necessary to optimize the parameters of 
the FRET AB Wizard on the Leica TCS SP5 II, such as the CFP and YFP transmission 
percentages and the spectral emission ranges for CFP and YFP, as previous experiments 
were performed on a Zeiss LSM 510 microscope (Organ-Darling et al., 2013). 
My second aim was to determine the molecular mechanism responsible for 
modulating the hERG-KvLQT1 interactions. More specifically, my focus was to 
determine whether hERG-KvLQT1 interactions are regulated by direct binding of cAMP 
at the CNBhD of hERG. apFRET experiments were also utilized to address this aim. In 
this case, rather than co-expressing wt proteins in HEK cells, the naturally occurring 
LQT1 mutant of hERG, V822M, which occurs in the CNBhD and renders the binding 
domain functionless but retain normal biosynthesis and trafficking, as reported by Cui et 
al. (2001), was co-expressed with wt KvLQT1. Utilizing the CNBhD hERG mutant was a 
direct way of assessing the role of the CNBhD in modulating the dynamics of hERG-
KvLQT1 interactions at the molecular level. 
 
 
Methods and Materials 
 
hERG Mutant Construct Creation 
The hERG-V822M-mCFP construct was created by Medeea Popescu ’17 and 
Amanda Papakyrikos ’14 by site-directed mutagenesis using the QuikChange Lightning 
multi site-directed mutagenesis kit (Agilent Technologies). The “m” in mCFP stands for 
monomerized. It was necessary to monomerize the CFP fluorophore to ensure that only a 





dimers if not monomerized. This could potentially lead to false positives during FRET 
experiments because the fluorophores themselves could be directly interacting with each 
other. 
 
Cell Culture and Transfection 
 
Human embryonic kidney 293 (HEK) cells were cultured in EMEM media 
(ATCC, product number 30-2003) with 10% FBS and 1% pen-strep (Life Technologies, 
catalog number 15070) under standard conditions and incubated at 37°C. For imaging, 
HEK cells were plated 24 hours before transfection on coverslips in tissue-culture treated 
6-well plates at a density of 50,000 cells/slip. HEK cells were transiently transfected 
following product literature using X-tremeGENE 9 (Roche) transfection reagent with a 
ratio of 2 μl X-tremeGENE:1 μg DNA. For wt protein samples, cells were transfected 
with hERG-mCFP (wt negative control), KCNQ1-CFP-YFP (wt positive control), or 
hERG-mCFP + KCNQ1-mYFP (wt FRET pair). For hERG mutant samples, cells were 
transfected with hERG-V822M-mCFP (mutant negative control), KCNQ1-CFP-YFP, or 
hERG-V822M-mCFP + KCNQ1-mYFP (mutant FRET pair). Co-transfections for FRET 
pairs used equal mounts (1 μg) for each plasmid. Transfected cells were allowed to grow 
for 48 hours before any experiments took place. The medium was replaced 24 hours post 
transfection. 
48 hours after transfection, intracellular cAMP levels were elevated through the 
application of 500 μM of the soluble cAMP analogue pCPT-cAMP (stock solution in 
dH2O) (Sigma-Aldrich, product number C3912) and 100 μM of the phosphodiesterase 





media. Cells were incubated with pCPT-cAMP and IBMX at 37°C for 5 minutes. After 
treatment, the cells were rinsed once with PBS. Following the first rinse, cells were fixed 
with 4% paraformaldehyde for 15 minutes. After fixing, the cells were rinsed 3X with 
PBS. The coverslips were mounted onto slides with Prolong Gold Diamond antifade 
mountant without DAPI (Life Technologies, catalog number P36934) and left to sit for 
30 minutes, after which the coverslips were sealed with clear nail polish. Throughout this 
entire procedure, the cells were covered with tinfoil to prevent the cells from being 
exposed to light. 
 
Confocal Imaging and Acceptor Photobleach FRET 
 
Acceptor Photobleach FRET (apFRET) experiments were performed on a Leica 
TCS SP5 II following the provided FRET AB Wizard program. The mCFP and mYFP 
fluorophores were excited with 458- and 514-nm lasers, respectively. The transmission 
percentages were held at 20% and 10% for the 458- and 514-nm laser lines, respectively. 
The spectral emission ranges for CFP and YFP were set to 470-510 nm and 580-650 nm, 
respectively. Eight-bit, 512 x 512 images of cells expressing the protein(s) were obtained 
with a 63X objective/1.40 oil UV at a zoom factor of 2 with a pinhole of 1 Airy units, 
corresponding to an image depth of 95.51 μm. For each cell, a circular region of interest 
(ROI) of 2.5 μm in diameter, representing the bleach ROI, was drawn in at the membrane 
of the cell, with approximately one half of the ROI on the cell and the other half in the 










Donor Pre 21.2 
Donor Post 21.18 
Acceptor Pre 45.69 
Acceptor Post 48.27 
Bleach Depth 0 
Efficiency 0 
Bleach Region 
Donor Pre 26.46 
Donor Post 38.6 
Acceptor Pre 54.25 
Acceptor Post 6.37 
Bleach Depth 0.88 
Efficiency 0.3146 
Figure 5. A visual representation of the apFRET protocol on Leica FRET AB Wizard 
software. This representative experiment demonstrates direct interactions between CFP and 
YFP fluorescent proteins directly linked together and fused to the COOH-terminus of 
KvLQT1 (KCNQ1-CFP-YFP) expressed in Human Embryonic Kidney (HEK) cells. The 
region of interest (ROI) 1 of cell was bleached with 514 nm laser at 30% transmission for 5 
seconds. ROI2 represents an unbleached, control region. (A) Representative images of cells 
expressing KvLQT1-CFP-YFP under FRET AB Wizard parameters pre-bleach. ROIs 1 and 
2 are zoomed in. (B) Representative images of cells in (A) post-bleach. ROIs 1 and 2 are 
zoomed in. The tables below represent the pre and post intensity values of the donor and 
acceptor provided by the Wizard. Bleach depth and efficiency were calculated based on 
these intensity values. Images were taken with a 63X objective and a zoom of 2X and 1 
Airy Unit on confocal microscope. Note: Images shown here have been contrast enhanced 










Photobleaching of the acceptor molecule (mYFP) was accomplished using the 
514 laser line at 30% transmission for 5 rapid scans of the bleach ROI, requiring 5 s. The 
Leica FRET AB Wizard quantified the mean donor and acceptor intensity in the bleach 
region over time. The FRET efficiency (Ef) was calculated as Ef = (Ipostbleach-
Iprebleach) x (100%/Ipostbleach), where I is the average mCFP (donor) intensity from 
the raw data in the bleach ROI for a given time point. FRET efficiencies below 0% were 
reported as 0 by the FRET AB Wizard, and therefore, these zero values were utilized as 
such in the data analyses. After running the apFRET experiment, it was necessary to go 
back to the original image and draw in another ROI of the same dimensions on the same 
cell in an area separate from the bleach region. This ROI acted as the control region, and 
the raw data was provided in a similar table as that of the bleach region (Fig. 5). 
Analogous equations used data from the control ROI to provide an internal, experimental 




 A 3-way ANOVA without interactions was performed to analyze an effect of 
group-type (positive control, negative control, or FRET pair), treatment-type (pCPT-
cAMP + IBMX treated or untreated), and mutant-type (wt or V822M hERG) across all 
samples to establish significance of group type, treatment type, and mutant type across all 
data points. A 2-factor ANOVA without interactions was also performed in order to 
determine the effect of treatment-type (pCPT-cAMP + IBMX treated or untreated) and 
mutant-type (wt or V822M hERG) across the FRET efficiencies of only the wt and 





necessary. ANOVA analyses were performed using R software. Significance was 
established at p < 0.05. 
 
Results 
Optimization of FRET AB Wizard Parameters 
Prior to performing apFRET experiments, the parameters of the FRET AB Wizard 
on a Leica TCS SP5 II were optimized. It was necessary to determine an optimal 
transmission percentage, which is the amount of light that actually hits the sample, for 
each laser to ensure that neither the CFP nor YFP fluorophore was getting bleached by 
their respective lasers during standard imaging. The basic purpose of these series of 
“experiments” was to optimize the percentage transmission for each laser so that when 
performing FRET experiments in the future, I am not presented with false positive and/or 
false negative results.  
In order to determine this setting, cells expressing hERG-mCFP or KvLQT1-
mYFP were subjected to 100 scans at varying percent transmissions to the CFP and YFP 
lasers, respectively. The argon laser was set at 20% power. Five ROI points were placed 
on various cells: 4 were placed in cells that are expressing CFP or YFP and 1 in the 
background. The average intensities of the first 10 frames and last 10 frames were 
compared, and the percent change between these values was determined. The percentage 
transmission for the 458-nm laser was changed in 5% increments starting from 10% up to 
40% to determine which percent transmission results in the most consistent levels of CFP 
intensities. The percentage transmission for the 514-nm laser was changed in 5% 





considerably brighter in intensity compared to CFP to begin with. These optimization 
experiments were performed on Chinese Hamster Ovary (CHO) cells expressing the 
protein of interest. 
At 40% transmission of the 458-nm laser, CFP expressing cells were over-
exposed and there was extensive background noise in the images (Figure 6A). At 40% 
transmission of the 458-nm laser, CFP intensities steadily decreased after cells were 
exposed to 100 consecutive scans, suggesting that this percent transmission was 










































 First 10 frames Last 10 frames Percent 
Difference 
ROI1 250.86 245.48 2.14 
ROI2 180.55 167.04 7.48 
ROI3 249.99 243.24 2.70 
ROI4 183.77 178.87 2.66 












The least amount of fluctuations in CFP intensities resulted at a percentage 

















Figure 6. 40% transmission of the 458 nm laser results in a noisy background for 
imaging and a relatively large percent change in CFP intensities over the course of 100 
consecutive scans (129 s duration). (A) A representative image of CHO cells expressing 
hERG-mCFP. Five ROIs of the same size were placed throughout cells expressing CFP. 
One ROI (ROI5 in pink) was placed in the background with no CFP fluorescence as a 
control. (B) A normalized graph measuring mean intensities within the ROIs over the 
course of scans. The table below includes the average intensity within each ROI for the 
first and last 10 frames. The percent change was calculated. Images were taken on the 63X 
objective at 1X zoom and 1 Airy Unit on the confocal microscope. Note: Images shown 


























 First 10 frames Last 10 frames Percent Difference 
ROI1 142.49 140.20 1.61 
ROI2 105.40 104.35 1.01 
ROI3 201.80 198.21 1.78 
ROI4 61.81 60.70 1.80 












A similar series of experiments were performed on CHOs expressing KvLQT1-
mYFP. The least amount of fluctuations in YFP intensities resulted at a percentage 
transmission of 10% of the 514-nm laser line (Figure 8). Note that while YFP intensity 
values themselves are quite low relative to the CFP intensity values, qualitatively YFP 
excited by the 514-nm laser at 10% transmission is brighter than CFP excited by the 458-











Figure 7. There is the least amount of fluctuation in CFP intensity when CFP is 
exposed to 458 nm laser line at 20% transmission for 100 consecutive scans (129 s 
duration). (A) A representative image of CHO cells expressing hERG-mCFP. Five 
ROIs of the same size were placed throughout cells expressing CFP. One ROI (ROI5 in 
pink) was placed in the background with no fluorescence as a control. (B) A graph 
measuring mean intensities within the ROIs over the course of scans. The table below 
includes the average intensity within each ROI for the first and last 10 frames. The 
percent change was calculated. Images were taken on the 63X objective at a zoom of 1X 


















































 First 10 frames Last 10 frames Percent Difference 
ROI1 5.97 5.80 2.93 
ROI2 4.95 4.81 2.88 





Figure 8. There is the least amount of fluctuation in YFP intensity when YFP fluorophore 
is exposed to 514 nm laser line at 10% transmission for 100 consecutive scans (129 s 
duration). (A) A representative image of CHO cells expressing KCNQ1-mYFP. Three ROIs 
of the same size were placed throughout cells expressing CFP. One ROI (ROI3 in purple) was 
placed in the background with no fluorescence as a control. (B) A graph measuring mean 
intensities within the ROIs over the course of scans. The table below includes the average 
intensity within each ROI for the first and last 10 frames. The percent change was calculated. 
Images were taken on the 63X objective at 1X zoom and 1 Airy Unit on the confocal 
microscope. Note: Images shown here have been contrast enhanced for better qualitative 






It was also necessary to address the issues of cross-excitation and emission 
bleedthrough between the CFP and YFP fluorophores. Upon excitation by the 458-nm 
laser, the CFP emission spectrum ranges from 460 to 535 nm. Upon excitation by the 
514-nm laser, the YFP emission spectrum is measured from 580 to 650 nm. Their 
spectral overlap makes CFP and YFP a suitable FRET pair for apFRET experiments. 
Cross-excitation occurs when the donor (CFP) is excited by the acceptor (YFP) laser or 
when the acceptor molecule (YFP) is excited by the donor (CFP) laser. Emission 
bleedthrough occurs for similar reasons as crosstalk. The phenomenon generally occurs 
when the emission of one fluorophore is detected by the channel of the second 
fluorophore, for example if the donor (CFP) emission were detected by the acceptor 
(YFP) channel, and vice versa. The following questions were directly addressed: (1) Does 
the CFP laser excite YFP (cross-excitation), and vice versa? (2) Is CFP emission detected 
by the YFP channel (emission bleedthrough), and vice versa? Therefore, it was necessary 
to determine the boundaries of the emission spectrum for separate detection of CFP and 
YFP.   
Initially, in order to address question (1) qualitatively, samples of CHOs 
expressing YFP (acceptor) only (KCNQ1-mYFP construct) were exposed to the 458-nm 
laser (CFP laser) at a 20% transmission. The YFP emission channel was turned on to see 
if the CFP laser was exciting YFP in the samples. The CFP emission detection range was 
arbitrarily set to 460–500 nm, and the YFP emission detection range was arbitrarily set to 
580–650 nm. As shown in Figure 9, the CFP laser did not excite YFP within this YFP 






The corollary to question (1), specifically if the YFP laser excites CFP, was also 
addressed similarly. In this case, cells expressing CFP only (hERG-mCFP) were exposed 
to the 514-nm laser at 10% transmission. The CFP emission channel was turned on to see 
if the YFP laser was exciting CFP in these samples. The CFP and YFP emission detection 
ranges were set to 460–500 nm and 580–650 nm, respectively, as in the first experiment. 
The YFP laser also did not excite CFP, as CFP emission was not strongly detectable 
within this CFP emission range (data not shown). 
In order to address question (2), samples of cells expressing CFP only (hERG-
mCFP) were excited by the CFP laser at 20% transmission. Both the CFP and YFP 
channels were turned on to determine if CFP emission was detected by the set YFP 
YFP channel CFP channel 
Figure 9. Cross-excitation of YFP by the CPF laser does not occur. CHO cell is 
expressing KvLQT1-mYFP. YFP and CFP emission channels are on. 458-nm laser 
was turned on and set at 20% transmission. CFP emission detection range: 460 nm–
500 nm; YFP emission detection range: 580 nm–650 nm. Images were taken on the 
63X objective at a zoom of 1X and 1 Airy Unit on the confocal microscope. Note: 







emission spectral range. The CFP and YFP emission detection ranges were set to 460–
500 nm and 580–650 nm, respectively, as in the first experiment. CFP emission was 
detected by the CFP channel, as expected, but was not strongly detected by the YFP 
channel (Figure 10).  
 
The same experiment was performed to test if YFP emission was detected by the 
CFP channel. In this case, cells expressing YFP only (KCNQ1-mYFP) were excited by 
the YFP laser at 10% transmission. Both the CFP and YFP emission channels were 
turned on to determine if YFP emission was detected by the set CFP emission spectral 
range. The CFP and YFP emission detection ranges were set to 460–500 nm and 580–650 
Figure 10. Emission bleedthrough of CFP as a result of CFP excitation into the YFP 
channel does not occur to a significant extent. CHO cell is expressing hERG-mCFP. 
YFP and CFP channels are on. 458-nm laser was turned on and set at 20% transmission. 
CFP emission detection range: 460 nm–500 nm; YFP emission range: 580 nm–650 nm. 
Images were taken on the 63X objective at a zoom of 1X and 1 Airy Unit on the 
confocal microscope. The red oval encompasses the minimal CFP emission 
bleedthrough detected in the YFP channel. Note: Images shown here have been contrast 
enhanced for better qualitative visualization in this thesis. 
 





nm, respectively, as in the first experiment. As shown in Figure 11, YFP emission from 
514-nm laser excitement was not detected by the CFP channel. 
 
 Furthermore, in order to determine the emission detection ranges for CFP and 
YFP that optimally minimize cross-excitation and emission bleedthrough, similar 
experiments were carried out as described above. In this case, the CFP-YFP linker 
soluble protein was expressed in CHOs, and each laser line was turned on individually 
with both the CFP and YFP channels on to determine the extent of detectable emission 
from each fluorophore by each laser. A total of 10 ROIs of the same dimensions were 
placed throughout the image field. Five ROIs were placed on cells that were fluorescing, 
while the other 5 were placed in the background (refer to Figure 12 for visualization of 
YFP channel CFP channel 
Figure 11. Emission bleedthrough of YFP as a result of YFP excitation into the 
CFP channel does not occur. CHO cell is expressing KvLQT1-mYFP. YFP and CFP 
channels are on. 514-nm laser was turned on and set at 10% transmission. CFP 
emission detection range: 460 nm–500 nm; YFP emission range: 580 nm–650 nm. 
Images were taken on the 63X objective at a zoom of 1X and 1 Airy Unit on the 
confocal microscope. Note: Images shown here have been contrast enhanced for better 






the experimental setup). The average intensity values of the ROIs were compared 
between each channel. For example, the average CFP intensity values of the ROIs within 
cells and in the background were compared to the average YFP intensity values of these 
same ROIs when only the CFP laser was on. In this case with the CFP laser on, the CFP 
intensity values were expected to be significantly greater than the YFP intensity values, 
thus addressing the concept of cross-excitation and emission bleedthrough. CFP and YFP 
intensity values were also collected with the YFP laser on. In this case, the YFP intensity 
values were expected to be significantly greater than the CFP intensity values. 
Ultimately, CFP and YFP emission detection ranges of 470-510 nm and 580-650 nm, 
respectively, were determined to most effectively minimize cross-excitation and emission 
bleedthrough between the two fluorophores, as assessed by student’s t-tests (Figure 12 










CFP Channel YFP Channel (A) 
CFP Channel YFP Channel (B) 
Figure 12. 470-510 nm and 580-650 nm are the optimal ranges for CFP and YFP 
emission detection. CHO cells are expressing soluble CFP-YFP. The same field of 
view is presented in (A) and (B). (A) CPF laser on at 20% transmission. CFP and YFP 
emission channels on. The low-level signaling in the YFP channel is likely due to 
emission bleedthrough of CFP into the YFP channel, rather than cross-excitation of 
YFP by the CFP laser. (B) YFP laser on at 10% transmission. CFP and YFP emission 
channels on. ROIs 1-5 are placed on cells, ROIs 6-10 are placed throughout the 
background. Images were taken on the 63X objective at a zoom of 1 and 1 Airy Unit 
on confocal microscope. Note: Images shown here have been contrast enhanced for 



















Optimization of Remaining FRET AB Parameters 
 Images for FRET experiments on the FRET AB Wizard were taken with the 
pinhole set at 1 Airy Unit, ensuring that true confocal images were taken, using a 63X 
1.40 oil UV objective. The 514-nm laser line for the bleach step of the experiment was 
optimally set to 30% transmission. The average bleach depth observed at this 
transmission percentage in the experiments with the positive controls and experimental 
CFP Laser On CFP Intensity YFP Intensity 
ROI1 35.55 17.25 
ROI2 34.7 10.7 
ROI3 50.35 20.05 
ROI4 51.6 16.95 
ROI5 60.05 17.6 
ROI6 5.45 4.95 
ROI7 2.9 1.25 
ROI8 3.2 3.9 
ROI9 3.2 2.15 
ROI10 4 5.9 
YFP Laser on 
 
  
ROI1 4.1 27.8 
ROI2 4.7 23.15 
ROI3 5.15 38.7 
ROI4 5.2 37.55 
ROI5 3.45 37.75 
ROI6 2 3.3 
ROI7 2 1.05 
ROI8 2.1 1.65 
ROI9 2 1.1 
ROI10 2 6.3 
Table 1 includes CFP and YFP intensity values corresponding to figures 11A and 
11B. Average CFP intensity was significantly greater than YFP intensity within cells 
(student’s t-test, p < 0.001). Average YFP intensity was significantly greater than CFP 






FRET pairs was 87% ± 3.4% (mean ± SD). The number of frames of the bleach step was 
5, which is equivalent to 5 seconds of exposure to the 514-nm laser. It is important to 
minimize the time it takes for bleaching because fluorophores are light sensitive 
molecules and thus will experience photobleaching when exposed to light for prolonged 
periods of time. Again, this is similar to why it was important to optimize the percent 
transmission to be utilized for each laser line (458-nm and 514-nm), so as to ensure that 
the corresponding fluorophore (CFP and YFP) experiences minimal photobleaching. The 
parameters utilized in the apFRET experiments in this study are presented in Table 2. 
  









apFRET Successfully Measures Interactions Between Wild-type hERG and KvLQT1 
 
Cells from three different transfections were pooled into one sample group and 
imaged on 18 individual days to account for variability in transfection efficiency, cell 
passage number, and normal fluctuations in the imaging hardware. Ideally, 10 HEK cells 
expressing the protein(s) of interest were identified per slide, and no more than 1 slide per 
sample was examined in a sitting. Therefore, a maximum of 30 cells, with 10 cells from 
each sample group (i.e. positive control, negative control, and FRET pair), were pooled 
for each sample group from apFRET experiments.  
HEKs were transfected with constructs for the wt condition: KCNQ1-CFP-YFP, 
hERG-mCFP, and hERG-mCFP + KCNQ1-mYFP, each in triplicate, which comprised a 
“single” transfection. A second and third round of transfections was also performed with 
these same constructs to allow for the variations discussed above and in case that not 
enough cells (at least 30) were present for apFRET experiments from the first round of 
transfection. The same procedures were followed for HEKs transfected with constructs 
for the mutant condition: KCNQ1-CFP-YFP, hERG-V822M-mCFP, and hERG-V822M-
mCFP + KCNQ1-mYFP.  
Average FRET efficiencies for experiments from all untreated and treated 
negative and treated positive controls for the wt and mutant conditions are presented in 












Table 3. FRET efficiencies for all samples evaluated by apFRET. 
Donor Acceptor Treatment Ef (%) Cf (%) n 
Positive controls 
KCNQ1-CFP-YFP  25.8 ± 7.67 0.65 ± 1.15 30 
KCNQ1-CFP-YFP 5 min; pCPT-cAMP + IBMX 26.7 ± 6.74 0.29 ± 0.65 30 
KCNQ1-CFP-YFP  27.1 ± 6.26 2.74 ± 3.23 30 
KCNQ1-CFP-YFP 5 min; pCPT-cAMP + IBMX 25.7 ± 6.70 1.39 ± 1.75 30 
Negative controls 
hERG-mCFP   2.50 ± 3.72 0.60 ± 1.53 30 
hERG-mCFP  5 min; pCPT-cAMP + IBMX 2.43 ± 2.46 0.18 ± 0.32 30 
hERG-
V822M-mCFP 
  3.52 ± 3.33 0.96 ± 1.38 30 
hERG-
V822M-mCFP 
 5 min; pCPT-cAMP + IBMX 2.04 ± 2.42 0.49 ± 0.89 30 
Experimental FRET pairs 
hERG-mCFP KCNQ1-mYFP  10.3 ± 3.44 0.49 ± 0.96 30 
hERG-mCFP KCNQ1-mYFP 5 min; pCPT-cAMP + IBMX 5.49 ± 3.19 0.06 ± 0.21 30 
hERG-
V822M-mCFP 
KCNQ1-mYFP  5.93 ± 3.84 1.18 ± 1.40 30 
hERG-
V822M-mCFP 
KCNQ1-mYFP 5 min; pCPT-cAMP + IBMX 5.57 ± 2.93 0.80 ± 1.10 30 
Values are mean ± SD. Ef, FRET efficiency; Cf, control for false-positive FRET efficiency. 
 
Firstly, we were interested in determining if apFRET was an effective method for 
measuring interactions between wt hERG and KvLQT1. We expected that the FRET 
efficiencies of experimental regions of the positive control, negative control, and wt 
FRET pair would be significantly different from one another. Histograms of the FRET 
efficiencies in the experimental and control regions of individual cells demonstrate 
distinct populations of FRET efficiencies in positive controls in both untreated and 
treated conditions, as expected because FRET should occur in the experimental regions 
but not in the control regions in both treatment conditions, for the donor and acceptor are 

























This distinction is not observed in the histograms for FRET efficiencies of the negative 
control samples, as expected (Figure 13). Positive controls demonstrated intramolecular 
FRET between the CFP and YFP fluorophores directly linked together via a short peptide 
sequence. Negative controls demonstrated no significant change in CFP emission in the 
absence of YFP, leading to very low values for FRET efficiencies and providing a 
sensitivity threshold for establishing protein-protein interactions. Figure 14 demonstrates 
the same trends between the untreated and treated conditions of the positive and negative 









Figure 13. Elevated cAMP levels abrogate wt hERG-KvLQT1 interactions, while 
mutant hERG-wt KvLQT1 interactions remain unchanged. Individual Ef and Cf values 
from each positive control, negative control, and FRET pair groups (wt and V822M hERG 
mutant) were plotted onto histograms. Top half represents data from all untreated samples, 
bottom half represents data from all samples treated with 500 μM pCPT-cAMP and 100 
μM IBMX. Cells were treated for 5 minutes. Left column represents data from positive 
control, negative control, and FRET pair of wt hERG and KvLQT1. Right column 
represents data from positive control, negative control, and FRET pair of V822M hERG 
and wt KvLQT1. Blue and red bars represent bleached and control (unbleached) ROIs, 
respectively, within the same cell (n=30 for each sample set). Data was collected from 










Positive Control: KvLQT1-CFP-YFP 
Treated 
Negative Control: hERG-mCFP 
Untreated 
Treated 
FRET Pair: hERG-mCFP+KvLQT1-mYFP 
Untreated 
Treated 
Positive Control: KvLQT1-CFP-YFP 
Untreated Treated 
Negative Control: hERG-V822M-mCFP 
Untreated Treated 
FRET Pair: hERG-V822M-mCFP+KvLQT1-mYFP 
Untreated Treated 
Figure 14. Data set from Figure 12 presented in box plots. Pink, blue, and green bars 







A 3-factor ANOVA with no interactions between the factors of treatment 
(untreated vs. treated), group (positive control, negative control, FRET pair), and mutant 
(wt hERG or V822M hERG) was performed in order to determine the effect of these 3 
conditions on FRET efficiency across all samples. The ANOVA was performed on FRET 
efficiency values from experimental regions only. A significant effect due to group type 
was observed (p < 0.001). Thus, we proceeded to make comparisons between mean Ef 
values of the positive control, negative control, and wt FRET pair using individual 
student’s t-tests. 
The mean Ef of the positive control was significantly greater than the mean Ef of 
both the negative control and the wt FRET pair (p < 0.05), as determined by student’s t-
tests. The mean Ef of the negative control was significantly less than the mean Ef of the 
wt FRET pair (p < 0.05), as determined by student’s t-tests. The mean Ef of the positive 
control was significantly greater than the mean Ef of the wt FRET pair (p < 0.05), as 
determined by student’s t-tests. This makes sense because in the positive control, the CFP 
and YFP fluorophores were directly fused together. Therefore, the Ef values of the wt 
positive control represent the maximum FRET efficiency that can be measured in this 
experimental and hardware design. Additionally, Ef cannot be 100% because the 
fluorophores physically take up space due to their size, and as a result, there will always 
be some distance between them. In the case of the wt FRET pair, the two proteins are co-
expressed, and therefore the CFP and YFP fluorophores would be localized even further 






Elevated cAMP Levels Modulate FRET Efficiencies Between Wild-type hERG and 
KvLQT1 
 
Average FRET efficiencies in untreated and pCPT-cAMP + IBMX treated HEKs 
expressing KvLQT1-CFP-YFP (positive control) were 25.8 ± 7.67% and 26.7 ± 6.74%, 
respectively. Average FRET efficiencies in the control regions in untreated and treated 
HEKs expressing KvLQT1-CFP-YFP were 0.65 ± 1.15% and 0.29 ± 0.65%, respectively. 
Average FRET efficiencies in untreated and treated HEKs expressing hERG-
mCFP (negative control) were 2.50 ± 3.72% and 2.43 ± 2.46%, respectively. Average 
FRET efficiencies in the control regions of untreated and treated HEKs expressing 
hERG-mCFP were 0.60 ± 1.53% and 0.18 ± 0.32%, respectively. pCPT-cAMP + IBMX 
treatment did not significantly affect FRET efficiencies in the positive and negative 
controls, as expected (Figure 14).  
Mediation of hERG-KvLQT1 interactions by cAMP may demonstrate the 
physiological regulation of these protein interactions. Because we hypothesized that 
cAMP directly binds to the CNBhD on the COOH-terminus of hERG, we wanted to first 
assess the overall effects elevated cAMP on hERG-KvLQT1 interactions to confirm 
whether cAMP plays a role at all. In order to address the role of intracellular cAMP on 
the interactions between hERG and KvLQT1, HEKs co-expressing wt hERG and 
KvLQT1 were exposed to pCPT-cAMP and IBMX treatment for 5 minutes in order to 
elevate intracellular cAMP levels as would physiologically occur in response to 
sympathetic stimulation.  
Because a significant effect due to pCPT-cAMP and IBMX treatment (p < 0.01) 





the FRET efficiencies of the untreated and treated wt FRET pair using a student’s t-test. 
Average FRET efficiencies in untreated and treated HEKs co-expressing wt hERG-mCFP 
and KvLQT1-mYFP were 10.3 ± 3.44 and 5.49 ± 3.19, respectively. Average FRET 
efficiencies in the control regions of untreated and treated HEKs expressing hERG-mCFP 
were 0.49 ± 0.96 and 0.06 ± 0.21, respectively. Thus, pCPT-cAMP + IBMX treatment 
resulted in a significant, 48% reduction in FRET efficiency in the wt FRET pair (p < 
0.05). These results support the hypothesis that cAMP levels modulate the direct 
interactions between wt hERG and KvLQT1. 
 
Elevated cAMP Levels Do Not Affect FRET Efficiencies Between V822M hERG Mutant 
and Wild-type KvLQT1 
 
Average FRET efficiencies in untreated and pCPT-cAMP treated HEKs 
expressing KvLQT1-CFP-YFP (positive control for the V822M hERG mutant) were 27.1 
± 6.26% and 25.7 ± 6.70%, respectively. Average FRET efficiencies in the control 
regions in the same untreated and treated HEKs expressing KvLQT1-CFP-YFP were 2.74 
± 3.23% and 1.39 ± 1.75%, respectively. Note that these average Cf values are 
significantly greater (p < 0.05) than the Cf values collected from the positive controls for 
the wt FRET pair, based on student’s t-tests. This may be due to issues with the 
machinery (microscope or laser) because the same construct was used as the positive 
control for both the wt and mutant FRET pairs. It would be worthwhile to create a new 
set of untreated and treated samples of all the constructs and perform another run of the 
experiments detailed in this thesis to determine if these variations in Cf values are normal 
before proceeding with future apFRET experiments. These differences could also be due 





experiments. It may be that the cells with the greater Cf values represent a sample of 
brighter-intensity cells at baseline compared to the cells with the lower Cf values. This 
potential issue of experimenter bias should also be addressed in future apFRET studies to 
determine if there is an effect of fluorescence intensity on FRET efficiency and to ensure 
that cells with high-intensity of fluorescence are not overly selected.  
Average FRET efficiencies in untreated and treated HEKs expressing hERG-
V822M-mCFP (negative control) were 3.52 ± 3.33% and 2.04 ± 2.42%, respectively. 
Average FRET efficiencies in the control regions of untreated and treated HEKs 
expressing hERG-V822M-mCFP were 0.96 ± 1.38 and 0.49 ± 0.89, respectively. pCPT-
cAMP and IBMX treatment did not significantly affect FRET efficiencies in the positive 
and negative controls, as expected (Figure 14).  
We hypothesized that cAMP plays a direct role in modulating the interactions 
between hERG and KvLQT1 through direct binding at the conserved CNBhD on the 
COOH-terminus of hERG versus an indirect role through the activation of PKA. In order 
to address the molecular mechanism through which cAMP induces its effects on the 
mediation of hERG-KvLQT1 interactions, the same series of apFRET experiments were 
performed on HEKs expressing the V822M mutant hERG and wt KvLQT1. The V822M 
mutation located in the CNBhD of hERG renders the domain functionless, thereby 
preventing cAMP from binding (Satler et al., 1996; Cui et al., 2001). HEKs co-expressing 
hERG-V822M-mCFP and KvLQT1-mYFP were treated with pCPT-cAMP and IBMX 
for 5 minutes to acutely elevate intracellular cAMP levels, as was done in cells co-





untreated and treated mutant FRET pair (hERG-V822M-mCFP + KvLQT1-mYFP), and 
we expected that there would be no significant difference between these values. 
Average FRET efficiencies in untreated and treated HEKs co-expressing hERG-
V822M-mCFP and wt KvLQT1-mYFP were 5.93 ± 3.84% and 5.57 ± 2.93%, 
respectively. Average FRET efficiencies in the control regions of untreated and treated 
HEKs expressing hERG-V822M-mCFP and wt KvLQT1-mYFP were 1.18 ± 1.40% and 
0.80 ± 1.10%, respectively. Based on the significant effect of group type and treatment 
type observed in the 3-factor ANOVA, we made within-group comparisons between 
untreated and treated mutant FRET pairs using student’s t-tests. pCPT-cAMP + IBMX 
treatment did not significantly change FRET efficiencies in the mutant FRET pair. These 
results tentatively demonstrate that elevated cAMP levels were unable to reduce the 
interactions between V822M hERG and KvLQT1.  
 
The Overall Effect of Elevated cAMP Levels on FRET Efficiencies Between Wild-type 
and CNBhD Mutant FRET Pairs is Inconclusive 
 
We were also interested in making a between-groups comparison between the 
mean Ef values of the treated wt FRET pair and the treated mutant FRET pair. We 
expected that the mean Ef value of the wt FRET pair for the treated condition would be 
significantly less than that of the mutant FRET pair for the same condition because the 
same interactions present in both of the untreated wt and mutant FRET pairs should not 
have been affected in the treated mutant FRET pair. No significant effect of mutant-type 
was initially observed in the 3-factor ANOVA. This result was not expected initially, but 
the lack of a significant effect makes sense because the 3-factor ANOVA included all of 





FRET pair. Therefore, in order to address the question above, a 2-factor ANOVA of the 
Ef values of the FRET pairs only was performed. The factors were treatment-type 
(untreated or pCPT-cAMP + IBMX treated) and mutant-type (wt or V822M hERG 
mutant). Narrowing down the data to include only the Ef values of the experimental 
FRET pairs, and thus taking out the group-type factor, helped to more precisely analyze 
the effects of treatment on hERG-KvLQT1 interactions. A significant effect of mutant-
type was observed (p < 0.001). A significant effect of treatment-type was also observed 
(p < 0.001). 
We went on to perform a student’s t-test between the mean Ef values of the 
treated wt and mutant FRET pairs. Student’s t-tests demonstrated that the average FRET 
efficiency of the wt FRET pair was significantly reduced with pCPT-cAMP and IBMX 
treatment (p < 0.05), while the average FRET efficiency of the FRET pair including the 
CNBhD mutant (hERG V822M) was unaffected by the same treatment (p < 0.05). 
However, the average FRET efficiency of the untreated CNBhD mutant FRET pair was 
significantly lower than the average FRET efficiency of the wt FRET pair (p < 0.05), 
suggesting that the CNBhD mutant (hERG V822M) may not associate with KvLQT1 to 
the same extent as wt hERG (Figure 15). Therefore, direct comparisons of treatment 


















































Figure 15.  Overall effect of elevated cAMP levels on FRET efficiencies between wt 
and CNBhD mutant FRET pairs is inconclusive. Green bars represent the FRET 
pairs of the data set in figure 12. Left column represents wt FRET pairs, right column 
represents mutant FRET pairs. Untreated: no pCPT-cAMP+IBMX; treated: 500 μM 
pCPT-cAMP + 100 μM IBMX for 5 min. A 2-factor ANOVA was performed, 
followed by student’s t-tests within and between groups. † indicates statistical 
significance (p < 0.05) between untreated and treated sample groups. * indicates 








The main goal of this study was to address the following hypothesis: Direct 
interactions between the α-subunit cardiac potassium channel proteins hERG and 
KvLQT1 are modulated by direct binding of cAMP to the CNBhD located on the COOH-
terminus of hERG. My first aim was to affirm that increased intracellular cAMP levels 
diminished wt hERG and KvLQT1 interactions using the Leica SP5 II confocal system. 
My second aim was to address the effects of elevated intracellular cAMP levels on 
V822M hERG mutant and wt KvLQT1 interactions. These proteins were expressed in 
HEK cells, and their interactions were assessed via apFRET experiments. 
Troubleshooting and optimization of apFRET parameters on the FRET AB Wizard of the 
Leica TCS SP5 II was essential, as apFRET experiments had not previously been 
performed on the current Leica system (Organ-Darling et al., 2013). I was able to 
successfully establish FRET AB parameters that were utilized throughout the series of 
experiments in this study.  
Wt FRET pairs with elevated cAMP levels were expected to have significantly 
decreased FRET efficiencies compared to “normal” cAMP levels, while the FRET 
efficiencies were not expected to be significantly different in the untreated and treated 
mutant FRET pairs. This is because it was originally hypothesized that cAMP directly 
binds to the CNBhD, thereby abrogating the direct interactions between hERG and 
KvLQT1, as assessed by a decrease in FRET efficiency. Therefore, in the wt FRET pair, 
it was expected that increasing intracellular cAMP levels with acute pCPT-cAMP + 
IBMX treatment would result in a significant decrease in FRET efficiency compared to 





possesses a non-functioning CNBhD, it was expected that increasing intracellular cAMP 
levels with the same treatment would not result in significant differences in FRET 
efficiencies from the untreated condition because cAMP would no longer bind to this 
domain to abrogate the interactions. 
A 3-factor ANOVA without interactions was performed to determine the effects 
of group-type, treatment-type, and mutant-type on FRET efficiencies. Significant effects 
imply that the means within each type differ more than would be expected by chance 
alone. Overall, treatment-type and group-type demonstrated significant effects on FRET 
efficiency. No significant effect on FRET efficiency was present within the mutant-type 
condition. Therefore, we proceeded to perform individual t-tests to make within-group 
comparisons between the mean Ef value of the untreated and treated wt FRET pair, and 
between the Ef value of the untreated and treated mutant FRET pair. 
Based on our current statistical analyses, FRET efficiency in pCPT-cAMP + 
IBMX treated HEKs expressing wt hERG and KvLQT1 was significantly lower than in 
untreated HEKs expressing the wt FRET pair. FRET efficiency in treated HEKs 
expressing the V822M hERG mutant and wt KvLQT1 was not significantly different 
from the FRET efficiency observed in untreated cells expressing the mutant FRET pair. 
These results were in accordance with the proposed expectations. 
A 2-factor ANOVA without interactions was also performed to determine the 
effects of treatment-type and group-type on FRET efficiencies of the wt and mutant 
FRET pairs only. While the first 3-factor ANOVA did not produce any significant effect 
of mutant-type on FRET efficiency, this may have been due to the fact that the FRET 





values should generally not change between wt and mutant conditions, and therefore may 
have attributed to the lack of significance. Thus, we narrowed down our data pool to 
include only the FRET efficiencies of the experimental wt and mutant FRET pairs in the 
2-factor ANOVA. Overall, treatment-type and mutant-type demonstrated significant 
effects on FRET efficiencies of the wt and mutant FRET pairs. Therefore, we proceeded 
to perform individual t-tests to make a between-group comparison between the FRET 
efficiency of the wt and mutant FRET pairs in the treated condition.  
We expected the FRET efficiency of the treated wt FRET pairs to be significantly 
lower than that of the treated mutant FRET pairs, assuming that the untreated wt and 
mutant FRET pairs exhibit the same baseline FRET efficiencies. Based on a student’s t-
test, the mean Ef values of the treated wt and mutant FRET pairs were not significantly 
different. However, this is due to the fact that the mean Ef values of the untreated wt and 
mutant FRET pairs were significantly different from one another (p < 0.05), based on a 
student’s t-test. Thus, we were unable to validly make this specific comparison. This 
difference was unexpected because we assumed, based on previous literature reports, that 
the V822M hERG mutant was essentially the same as wt hERG in all aspects except for 
the loss of function of the CNBhD (Cui et al., 2001). Therefore, we did not expect the 
V822M hERG mutant to bind cAMP, but we did expect it to traffic normally through the 
secretory pathway and localize normally to the cell membrane. However, we observed 
that there were some unexpected trafficking issues with the V822M mutant. 
Qualitatively, the mutant hERG did not appear to traffic successfully to the cell 






Because the FRET efficiencies for the wt and mutant FRET pairs in the untreated 
condition were significantly different from one another, comparisons between treated wt 
and treated mutant FRET pairs cannot be made with confidence and the biological 
significance of statistical tests is unclear. However, because the results appear skewed 
due to an intrinsic, unexpected problem with the V822M mutant, the ANOVA does not 
accurately account for the unexpected variance in the FRET efficiencies of the untreated 
mutant FRET pair. Because there is initially an unexpected significant difference between 
the FRET efficiencies of the untreated wt and mutant FRET pairs, further comparisons 
could not be made with confidence. 
One important factor to consider when discussing the discrepancy in the expected 
and actual results is the trafficking of the V822M hERG mutant. Mutations in the 
CNBhD of hERG have been attributed to its inability to bind cyclic nucleotides and/or its 
improper trafficking (Cui et al., 2001). The reason we chose to work with the V822M 
mutant hERG was because we expected normal trafficking of the mutant to the 
membrane (Cui et al., 2001), and therefore we expected that FRET efficiencies would be 
similar between the wt and mutant FRET pairs. However, this was not the case. 
Additionally, when cells expressing the hERG mutant were visualized on the confocal 
microscope, hERG trafficking appeared to be disrupted based on the presence of punctate 
clusters and/or accumulations of CFP throughout the cell before reaching the membrane. 
These clusters are also usually “bright” spots on imaging, often reaching saturated values 
under our standard imaging protocols. Saturation poses an issue for quantification of 





expression of CFP in cells expressing the hERG mutant was not as homogenous as in 
cells expressing wt hERG-mCFP. 
The results corresponding to the wt FRET pair are in accordance with 
expectations as well as with the results of previous studies. Organ-Darling et al. (2013) 
also found that elevated intracellular cAMP levels resulted in decreased FRET efficiency 
in cells expressing wt hERG and KvLQT1. Cui et al. (2000) saw that K
+
 current 
amplitude decreased within 3 minutes of pCPT-cAMP application, and more specifically 
that IKr decreased by 40%, suggesting that cAMP plays a role in hERG function. 
These data do not necessarily confirm my initial hypothesis, but it also does not 
refute the alternative hypothesis involving the role of PKA phosphorylation of either 
hERG or KvLQT1, or both. Even in the presence of a mutated, nonfunctional CNBhD, 
the effects of elevated cAMP could still have resulted in hERG-KvLQT1 interaction 
abrogation via PKA activation and phosphorylation of either or both of these channels.  
In light of recent literature reports and growing consensus in the field, we adopt 
the alternative hypothesis that direct hERG-KvLQT1 interactions are modulated by 
cAMP-dependent PKA phosphorylation of either hERG or KvLQT1, or both. There is 
increasing evidence in favor of the PKA-mediated mechanism over the direct role of the 
CNBhD. Firstly, there is convincing structural, biophysical, and electrophysiological data 
supporting the view that the CNBhD of KCNH channels, including hERG, does not 
physically bind cyclic nucleotides. As introduced earlier, Brelidze et al., Marques-
Carvalho et al., and Li et al. have demonstrated evidence that cyclic nucleotides do not 
directly bind to the CNBhD (Brelidze et al., 2009; Marques-Carvalho et al., 2012; Li et 





cyclic nucleotides, it has been shown that the CNBhDs in KCNH channels bind other 
ligands, particularly intrinsic ligands, which regulate channel activity (Haitin et al., 2013; 
Gustina and Trudeau, 2011). Interestingly, Haitin et al. (2013) showed that the CNBhD 
of KCNH channels instead interact directly with the eag domain of the amino terminus to 
regulate channel function and gating kinetics. There have also been reports that the Per-
Arnt-Sim (PAS) domain in the cytoplasmic amino-terminal region of hERG directly 
interacts with the CNBhD in the COOH-terminus, thereby regulating slow deactivation of 
the channel (Gustina and Trudeau, 2011). These findings suggest that the CNBhD may 
have evolved other functions that are more directly involved in regulating KCNH channel 
activity.  
Secondly, the mechanism of the cAMP-dependent PKA-mediated 
phosphorylation of KCNH2 channels has been relatively well delineated. There are 4 
identified PKA phosphorylation sites located on hERG: aa 283, 890, 895, and 1137 
(Thomas et al., 1999). Amino acids 890 and 895 are located within the CNBhD. This 
already indicates to us that PKA phosphorylation of hERG occurs. Thomas et al. (1999) 
mutated the PKA phosphorylation sites to alanines and showed that this inhibited hERG 
activation. Utilizing that same phosphonull mutants, PKA inhibitors, 
immunoprecipitation, and electrophysiology, Cui et al. (2000) also demonstrated that 
cAMP-dependent PKA phosphorylation of hERG occurs, resulting in accelerated 
deactivation and a rightward shift in voltage dependence of activation, making the 
channel less likely to open in response to an action potential. Chen et al. (2009) also 
demonstrated that PKA phosphorylation of hERG as a result of elevated intracellular 





hERG does likely occur and is involved in a variety of cellular functions (Chen et al., 
2009). 
However, the role of PKA phosphorylation of hERG on modulating hERG-
KvLQT1 interactions is still unclear, and therefore a biological question to be addressed 
by the Darling lab. β-adrenergic stimulation via cAMP/PKA-dependent pathways 
attenuates IKr, while it enhances IKs (Cheng et al., 2014). This suggests that the 
phosphorylation of hERG may somehow disrupt interactions between hERG and 
KvLQT1, maybe allowing the density of KvLQT1 at the membrane surface to increase, 
thus increasing IKs, while hERG remains below the surface of the membrane.  
Limitations of the FRET methodology must be considered when interpreting these 
results. Resolution is limited, so we do not know if the population of proteins we are 
looking at in a single ROI when performing apFRET experiments is actually located in 
the cell membrane. It is possible that that some of the proteins that are measured in our 
FRET experiments are actually located right below the surface of the membrane, maybe 
acting as the “reserve pool” necessary under certain physiological conditions. However, 
if this were the case and our results were based off of these proteins, then the functional 
relevance of our data is limited because these proteins are not functional, or letting 
through current, when they are not in the plasma membrane. One way to address this 
would be ideally to perform electrophysiology experiments in tandem with the FRET 
experiments. If changes in IKr and IKs currents after elevated intracellular cAMP levels are 
measurable, at least we can be sure that some of the FRET occurred between hERG and 
KvLQT1 at the membrane. Changes in these currents would be functional evidence that 





IKr and IKs observed in the transgenic rabbit models of LQTS thought to be due to the 
direct interactions (Brunner et al., 2008). The Darling lab is currently collaborating with 
the Cameron lab, which is addressing these questions with electrophysiology. However, 
maybe more urgently, it may be worthwhile to perform these series of experiments again 
using a different CNBhD of hERG that does not display any of the trafficking issues 
observed in the V822M mutant because the current results are inconclusive. This is 
currently being executed with the R823Q hERG mutant by other members of the Darling 
lab. 
The significance of this pathway regulating hERG-KvLQT1 interactions has not 
yet been well characterized. It could be that cAMP-dependent phosphorylation of hERG 
located right below the surface of the membrane causes the conformational change 
necessary to dissociate hERG from KvLQT1 in response to β-adrenergic stimulation and 
trigger the delivery of KvLQT1 channels to the plasma membrane where they can be 
functional, thus adding to the growing IKs current under sympathetic stimulation. This 
response would then lead to increased IKs and shorter APDs, thus promoting a faster 
heartbeat to address the cause of the stimulation. If the interactions are indeed occurring 
at the surface of the cell, it is possible that phosphorylation of hERG causes the necessary 
conformational change to dissociate hERG from KvLQT1 while also allowing the 
changes in channel gating and function to occur, thus resulting in decreased hERG 
activation and IKr current density, as observed by Thomas et al. (1999) and Cui et al. 
(2000). Maybe the dissociation of hERG from KvLQT1 then promotes the necessary 






While I have focused mainly on hERG, it may also be worthwhile to consider 
modifications of KvLQT1 as potentially regulating hERG-KvLQT1 interactions. The S27 
KCNQ1 phosphorylation site has already been identified and the effects of cAMP-
dependent phosphorylation of the N-terminus of KvLQT1 by PKA have been generally 
well-established (Barhanin et al., 1996; Kurokawa et al., 2003). Therefore, it would be of 
interest to consider the role of KvLQT1 phosphorylation in the modulation of the direct 
interactions between hERG and KvLQT1. 
In order to address the new hypothesis that direct hERG-KvLQT1 interactions are 
modulated by cAMP-dependent PKA phosphorylation of either hERG or KvLQT1, or 
both, the same series of experiments performed in this study can be performed with 
phosphonull and phosphomimetic mutants of hERG and KvLQT1. Currently, the Darling 
lab has created a number of hERG phosphorylation mutations based on the 
phosphorylation sites on hERG that have been identified by Cui et al. (2001). The 
phosphonull mutants, where a serine or threonine has been substituted with alanine, 
prevents the phosphorylation of these particular amino acid sites. Phosphonull mutants of 
KvLQT1 are also being created to address the new hypothesis. With these mutants, then, 
we can determine if there are any significant changes in the interactions between hERG 
and KvLQT1. Ultimately, we can also determine if there are any functional changes in 
either of the proteins as a result of the inability of hERG and/or KvLQT1 to be 
phosphorylated. The phosphomimetic mutants of hERG and KvLQT1, where a serine or 
threonine has been substituted with an aspartate or glutamate, essentially mimics the 
phosphorylation state even in the absence of elevated cAMP levels. Therefore, with these 





interactions before and after elevating intracellular cAMP levels in these series of 
experiments. 
In the case of the phosphonull mutants, we would not expect to see a significant 
difference in FRET efficiencies before and after increasing intracellular cAMP levels if 
hERG-KvLQT1 interactions are regulated by PKA phosphorylation of hERG and/or 
KvLQT1. FRET efficiencies should remain the same because phosphorylation of hERG 
and KvLQT1 at these particular sites would no longer occur, and thus the interactions 
would remain the same. In the case of the phosphomimetic mutants, we would not 
expect, again, to see a significant difference in FRET efficiencies before and after 
increasing intracellular cAMP levels because the phosphorylation sites of hERG and 
KvLQT1 in the mutants would structurally appear phosphorylated. If either of these 
comparisons were significantly different from one another, then that would suggest that 
cAMP is involved in a separate mechanism from the PKA-pathway that is responsible for 
modulating the hERG-KvLQT1 interactions. Ultimately, we would want to compare the 
FRET efficiencies between the phosphonull and -mimetic mutants in the elevated or 
baseline cAMP level state and demonstrate that they are significantly different from one 
another. More specifically, we would expect that the FRET efficiency of the 
phosphomimetic mutants would be significantly lower than that of the phosphonull 
mutants because we hypothesize that hERG and KvLQT1 would be always be interacting 
in the null mutants, while the interactions would be decreased in the mimetic mutants. 
This would then suggest that the activation of PKA by cAMP and PKA phosphorylation 





Overall, understanding the underlying molecular mechanism responsible for 
modulating the interactions between hERG and KvLQT1 could ultimately provide insight 
into the manifestation of LQT syndrome and other cardiac disorders and arrhythmias as 
well as the molecular mechanisms that shorten the APD in times of elevated heart rate in 
normal physiology, such as sympathetic surge. Mutations in the CNBhD of hERG have 
been identified that are associated with LQT2, including the V822M mutation (Splawski 
et al., 2000). Some of these mutations have been shown to disrupt protein trafficking and 
channel properties (Cui et al., 2001). Mutations have also been characterized in KCNQ1 
that are associated with LQT1. The interplay between hERG and KvLQT1 is especially 
important during times of stress or exercise, when IKs increases as a response to an 
increase in sympathetic tone, to maintain regulated cardiac repolarization (Bilicski et al., 
2009). Therefore, disruptions in proper hERG or KvLQT1 function can cause detrimental 
effects. There is evidence demonstrating hERG-KvLQT1 interactions in disease states. 
Most notably, the transgenic rabbit models of LQTS utilized by Brunner et al. (2008) 
demonstrated the presence of a functional, mutual downregulation of IKr and IKs. Bilicski 
et al. (2009) also demonstrated that a mutation in KCNQ1 associated with LQT1 
decreased membrane localization of hERG, completely eliminating the “repolarization 
reserve.” Determining the exact mechanism by which cAMP may play a role in hERG-
KvLQT1 interactions may then provide insight into the cause of these phenomena. Thus, 
ultimately, elucidating the mechanism of hERG-KvLQT1 interactions at the molecular 
level may help to better characterize therapeutic targets and clinical intervention for 
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